In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 2, 2014, Pages 874-879

  Hagihara, Mao ^a,b   Housman, Seth T ^a   Nicolau, David P ^a   Kuti, Joseph L ^a  

^a HARTFORD HOSPITAL   (United States)

^b AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DORIPENEM; POLYMYXIN B; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CELL DENSITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG POTENTIATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; PRIORITY JOURNAL; SIMULATION; TREATMENT RESPONSE;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CARBAPENEMS; COLONY COUNT, MICROBIAL; DRUG COMBINATIONS; DRUG SYNERGISM; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; MODELS, STATISTICAL; POLYMYXIN B;

EID: 84893505135     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01624-13     Document Type: Article

References (38)

1. Garnacho-Montero J, Amaya-Villar R. 2010. Multi-resistant Acinetobacter baumannii infections: epidemiology and management. Curr. Opin. Infect. Dis. 23:332-339. http://dx.doi.org/10.1097/QCO.0b013e32833ae38b.
2. Murray CK, Obremskey WT, Hsu JR, Andersen RC, Calhoun JH, Clasper JC, Whitman TJ, Curry TK, Fleming ME, Wenke JC, Ficke JR, Prevention of Combat-Related Infections Guidelines Panel. 2011. Prevention of infections associated with combat-related extremity injuries. J. Trauma 71(2 Suppl 2):S235-S237. http://dx.doi.org/10.1097/TA.0b013e318227ac5f.
3. Sandiumenge A, Rello J. 2012. Ventilator-associated pneumonia caused by ESKAPE organisms: cause, clinical features, and management. Curr. Opin. Pulm. Med. 18:187-193. http://dx.doi.org/10.1097/MCP.0b013e328351f974.
4. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12. http://dx.doi.org/10.1086/595011.
5. Kwa AL, Low JG, Lee E, Kurup A, Chee HL, Tam VH. 2007. The impact of multidrug resistance on the outcomes of critically ill patients with Gram-negative bacterial pneumonia. Diagn. Microbiol. Infect. Dis. 58: 99-104. http://dx.doi.org/10.1016/j.diagmicrobio.2006.11.014.
6. Esterly JS, Griffith M, Qi C, Malczynski M, Postelnick MJ, Scheetz MH. 2011. Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections. Antimicrob. Agents Chemother. 55:4844-4849. http://dx.doi.org/10.1128/AAC.01728- 10.
7. Shields RK, Clancy CJ, Gillis LM, Kwak EJ, Silveira FP, Massih RC, Eschenauer GA, Potoski BA, Nguyen MH. 2012. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One 7:e52349. http://dx.doi.org/10.1371/journal.pone.0052349.
8. Bonomo RA, Szabo D. 2006. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin. Infect. Dis. 43: S49-S56. http://dx.doi.org/10.1086/504477.
9. Adams-Haduch JM, Onuoha EO, Bogdanovich T, Tian GB, Marschall J, Urban CM, Spellberg BJ, Rhee D, Halstead DC, Pasculle AW, Doi Y. 2011. Molecular epidemiology of carbapenem-nonsusceptible Acinetobacter baumannii in the United States. J. Clin. Microbiol. 49:3849-3854. http://dx.doi.org/10.1128/JCM.00619- 11.
10. Mera RM, Miller LA, Amrine-Madsen H, Sahm DF. 2010. Acinetobacter baumannii 2002-2008: increase of carbapenem-associated multiclass resistance in the United States. Microb. Drug Resist. 16:209-215. http://dx.doi.org/10.1089/ mdr.2010.0052.
11. Mendes RE, Bell JM, Turnidge JD, Castanheira M, Jones RN. 2009. Emergence and widespread dissemination of OXA-23,-24/40, and-58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program. J. Antimicrob. Chemother. 63: 55-59. http://dx.doi.org/10.1093/jac/ dkn434.
12. Falagas ME, Kasiakou SK. 2005. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin. Infect. Dis. 40:1333-1341. http://dx.doi.org/10.1086/429323.
13. Henwood CJ, Gatward T, Warner M, James D, Stockdale MW, Spense RP, Towner KJ, Livermore DM, Woodford N. 2002. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J. Antimicrob. Chemother. 49:479-487. http://dx.doi.org/10.1093/jac/ 49.3.479.
14. Pachón-Ibáñez ME, Jiménez-Mejías ME, Pichardo C, Llanos AC, Pachón J. 2004. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimcrob. Agents Chemother. 48:4479-4481. http://dx.doi.org/10.1128/AAC.48.11. 4479-4481.2004.
15. Scheetz MH, Qi C, Warren JR, Postelnick MJ, Zembower T, Obias A, Noskin GA. 2007. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51:1621-1626. http://dx.doi.org/10. 1128/AAC.01099-06.
16. Principe L, D'Arezzo S, Capone A, Petrosillo N, Visca P. 2009. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann. Clin. Microbiol. Antimicrob. 8:18. http://dx.doi.org/10.1186/1476-0711-8-18.
17. Urban C, Mariano N, Rahal JJ. 2010. In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob. Agents Chemother. 54:2732-2734. http://dx.doi.org/10.1128/AAC.01768-09.
18. Lim TP, Tan TY, Lee W, Sasikala S, Tan TT, Hsu LY, Kwa AL. 2011. In-vitro activity of polymyxin B, rifampicin, tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii in Singapore. PLoS One 6:e18485. http://dx.doi.org/10.1371/journal.pone.0018485.
19. Tan TY, Lim TP, Lee WHL, Sasikala S, Hsu LY, Kwa AL-H. 2011. In vitro antibiotic synergy in extensively drug-resistant Acinetobacter baumannii: the effect of testing by time-kill, checkerboard, and Etest methods. Antimicrob. Agents Chemother. 55:436-438. http://dx.doi.org/10.1128/AAC.00850-10.
20. Sheng WH, Wang JT, Li SY, Lin YC, Cheng A, Chen YC, Chang SC. 2011. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn. Microbiol. Infect. Dis. 70:380-386. http://dx.doi.org/10.1016/j. diagmicrobio.2011.03.003.
21. Peck KR, Kim MJ, Choi JY, Kim HS, Kang CI, Cho YK, Park DW, Lee HJ, Lee MS, Ko KS. 2012. In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii, including colistin-or tigecycline-resistant isolates. J. Med. Microbiol. 61: 353-360. http://dx.doi.org/10.1099/jmm.0.036939-0.
22. O'Hara JA, Ambe LA, Casella LG, Townsend BM, Pelletier MR, Ernst RK, Shanks RMQ, Doi Y. 2013. Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains. Antimicrob. Agents Chemother. 57:2103-2108. http://dx.doi.org/10.1128/AAC.02501-12.
23. Clinical and Laboratory Standards Institute. 2007. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-7th ed. CLSI document M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
24. Zavascki AP, Goldani LZ, Cao G, Superti SV, Lutz L, Barth AL, Ramos F, Boniatti MM, Nation RL, Li J. 2008. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin. Infect. Dis. 47:1298-1304. http://dx.doi.org/10.1086/592577.
25. Koomanachai P, Kim A, Nicolau DP. 2009. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. J. Antimicrob. Chemother. 63:982-987. http://dx.doi.org/10.1093/jac/dkp056.
26. Rubino CM, Forrest A, Bhavnani SM, Dukart G, Cooper A, Korth-Bradley J, Ambrose PG. 2010. Tigecycline population pharmacokinetics in patients with community-or hospital-acquired pneumonia. Antimicrob. Agents Chemother. 54:5180-5186. http://dx.doi.org/10.1128/AAC.01414-09.
27. Housman ST, Hagihara M, Nicolau DP, Kuti JL. 2013. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem, and tigecycline alone and in combination against multidrugresistant Acinetobacter baumannii. J. Antimicrob. Chemother. 68:2296-2304. http://dx.doi.org/10.1093/jac/dkt197.
28. Wiskirchen DE, Koomanachai P, Nicasio AM, Nicolau DP, Kuti JL. 2011. In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase. Antimicrob. Agents Chemother. 55:1420-1427. http://dx.doi.org/10. 1128/AAC.01253-10.
29. Pillai SK, Moellering RC, Eliopoulous GM. 2005. Antimicrobial combinations, p 365-440. In Lorian V (ed), Antibiotics in laboratory medicine, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
30. Firsov AA, Vostrov SN, Shevchenko AA, Cornaglia G. 1997. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrob. Agents Chemother. 41:1281-1287.
31. Li C, Sutherland CA, Nightingale CH, Nicolau DP. 2004. Quantitation of tigecycline, a novel glycylcycline [corrected] by liquid chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 811:225-229. http://dx.doi.org/10.1016/j.jchromb.2004.09.011.
32. Michalopoulos A, Falagas ME. 2010. Treatment of Acinetobacter infections. Expert Opin. Pharmacother 11:779-788. http://dx.doi.org/10.1517/ 14656561003596350.
33. Peterson PJ, Labthavikul P, Jones CH, Bradford PA. 2006. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by checkerboard and time-kill kinetic analysis. J. Antimicrob. Chemother. 57:573-576. http://dx.doi.org/10.1093/jac/dki477.
34. Ozbek B, Otük G. 2010. In vitro activities of tigecycline alone and in combination with colistin sulfate or sulbactam against carbapenemsusceptible and-resistant Acinetobacter baumannii strains isolated from intensive care units. Int. J. Antimicrob. Agents 36:191-192. http://dx.doi.org/10.1016/j. ijantimicag.2010.04.004.
35. Mutlu Yilmaz E, Sunbul M, Aksoy A, Yilmaz H, Guney AK, Guvenc T. 2012. Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii. Int. J. Antimicrob. Agents 40:332-336. http://dx.doi.org/10.1016/j.ijantimicag.2012.06.003.
36. Dudhani RV, Turnidge JD, Nation RL, Li J. 2010. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J. Antimicrob. Chemother. 65:1984-1990. http://dx.doi.org/10.1093/jac/dkq226.
37. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhão RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP. 2013. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for dosage regimens. Clin. Infect. Dis. 57:524-531. http://dx.doi.org/10.1093/cid/cit334.
38. Lee HJ, Bergen PJ, Bulitta JB, Tsuji B, Forrest A, Nation RL, Li J. 2013. Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/ pharmacodynamic model. Antimicrob. Agents Chemother. 57:3738-3745. http://dx.doi.org/10.1128/AAC.00703-13.